Change from baseline in symptoms through Day 10 defined as aggregated Food and Drug Administration (FDA) COVID-19 questionnaire score from baseline through Day 10 comparing UNI91103 vs placebo. Safety of UNI91103 nasal spray as assessed by adverse events, vital signs, hematology, and clinical chemistry

Change from baseline in symptoms through Day 10 defined as aggregated Food and Drug Administration (FDA) COVID-19 questionnaire score from baseline through Day 10 comparing UNI91103 vs placebo. Safety of UNI91103 nasal spray as assessed by adverse events, vital signs, hematology, and clinical chemistry